Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C.

Authors

Girish S. Kulkarni

University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

Girish S. Kulkarni , Shilpa Gupta , Andrea Necchi , Neal D. Shore , Hema Kishore Dave , Ekta Kapadia , Qing Zhao , Ashish M. Kamat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Phase 2 KEYNOTE-057 cohort C: Pembrolizumab (pembro) with vibostolimab or favezelimab for patients (pts) with high-risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC).

First Author: Neal D. Shore

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.

First Author: Ashish M. Kamat

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC).

First Author: Thierry Andre

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC).

First Author: Ashish M. Kamat